Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)

Fig. 4

a Urine liver-type fatty-acid binding protein (L-FABP)-to-creatinine ratio, b urine type IV collagen-to-creatinine ratio, c urine 8-hydroxy-2′-deoxyguanosine (8-OHdG)-to-creatinine ratio, d pentosidine, e diacron-reactive oxygen metabolites (d-ROMs), and f biological antioxidant potential (BAP) at baseline and after 24 weeks of add-on dapagliflozin treatment (week 24). Change from baseline to week 24 was analyzed using a one-sided paired t-test

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840